ABSTRACT
Cervical cancer is a highly preventable malignancy caused by high-risk human papillomavirus
(hrHPV) but is not fully prevented, especially in low- and middle-income countries (LMIC).
Women living with HIV (WWH) have higher rates of hrHPV infection and 6-fold higher rates of
invasive cervical cancer. Sub-Saharan Africa carries the highest burden of cervical cancer
globally, as well as the highest global burden of HIV. The Einstein/Rwanda Research and
Capacity Building Program (ER-RCBP) has been conducting research in cervical cancer
prevention for Rwandan WWH since 2005, conducting community- and clinic-based research in
screening uptake, screening modalities, assessing HPV vaccine effectiveness, evaluating how
to implement innovative screening approaches, and developing pathology and molecular
laboratory capacity. We have enrolled nearly 10,000 women WWH and 3,000 HIV-negative
women in studies of cervical HPV infection and disease. ER-RCBP’s primary partner in this
application, and in prior research in HIV services and cervical cancer prevention, is the Rwanda
Biomedical Center (RBC), the implementation arm of Rwanda’s Ministry of Health for healthcare
delivery and research. Rwanda has an extremely effective HIV healthcare program, an equally
effective program for HPV vaccination of girls, and has recently launched a cervical cancer
screening and prevention program with primary HPV testing followed by visual inspection of the
cervix and immediate treatment with thermal ablation, if indicated, for screen-positive women.
Rwanda is thus an ideal location for testing strategies for effective cervical cancer screening in a
low-income country with a high burden of HIV, cervical cancer, and a large unscreened
population. We propose here a clinical trials site in Rwanda as part of the CASCADE Clinical
Trials Network for Cervical Cancer Prevention. Lessons learned in Rwanda can be generalized
to many low-income countries in sub-Saharan Africa.